NCT00141531 is a Phase 2 clinical trial of Apaziquone in Bladder Neoplasms, sponsored by Spectrum Pharmaceuticals, Inc.

Who is sponsoring NCT00141531?

NCT00141531 is sponsored by Spectrum Pharmaceuticals, Inc.

What drugs are being tested in NCT00141531?

Interventions in NCT00141531: Apaziquone.

What condition does NCT00141531 study?

NCT00141531 studies Bladder Neoplasms.

Is NCT00141531 still recruiting?

NCT00141531 is currently completed. Last updated 13 June 2012.

Last reviewed 2012-06-13 · How we verify

NCT00141531

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase II Study of Intravesical Instillation of EOQUIN™ in High Risk Superficial Bladder Cancer

Completed Phase 2 Last updated 13 June 2012

What this trial tests

Phase 2 trial testing Apaziquone in Bladder Neoplasms in 53 participants. Completed in 1 December 2009.

Timeline

1 July 2005

Primary endpoint
1 December 2009

1 December 2009

Quick facts

Lead sponsor	Spectrum Pharmaceuticals, Inc
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	53
Start date	1 July 2005
Primary completion	1 December 2009
Estimated completion	1 December 2009
Sites	1 location across Netherlands

Drugs / interventions tested

Apaziquone — full drug profile →

Conditions studied

Bladder Neoplasms — all drugs for Bladder Neoplasms →

Sponsor

Spectrum Pharmaceuticals, Inc — full company profile →

Who can join

18 and older, any sex, with Bladder Neoplasms. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Time to progression / Duration of remission following transurethral resection of superficial bladder cancer
Time frame: 18 months

Sponsor's own description

A non-randomized, open-label phase II study to explore the feasibility, time to recurrence, duration of response and safety of the adjuvant intravesical instillation of EOquin (apaziquone) in patients with high-risk superficial bladder tumors, and the response and duration of response in patients with carcinoma in situ of the bladder.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Metabolic rewiring in the promotion of cancer metastasis: mechanisms and therapeutic implications.
Wei Q, Qian Y, Yu J, Wong CC. · · 2020 · cited 145× · PMID 32839493 · DOI 10.1038/s41388-020-01432-7
Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy.
Baran N, Konopleva M. · · 2017 · cited 105× · PMID 28137923 · DOI 10.1158/1078-0432.ccr-16-0895

Verify or expand the search:

Other trials of Apaziquone

Trials testing the same drug.

NCT02563561 — A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumo · Phase 3 · terminated

Other recruiting trials for Bladder Neoplasms

Currently open trials in the same condition.

NCT05072600 — Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer · Phase 2 · recruiting

Other Spectrum Pharmaceuticals, Inc trials

Trials by the same sponsor.

NCT05378763 — A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 2 · Phase 3 · suspended
NCT04981704 — A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacok · Phase 1 · completed
NCT04402008 — Study of Poziotinib in Japanese Patients With NSCLC · Phase 1, PHASE2 · terminated
NCT04436562 — Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male Subjects · Phase 1 · completed
NCT04187898 — Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00141531 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Spectrum Pharmaceuticals, Inc
Last refreshed: 13 June 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00141531.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing